Lb Pharmaceuticals (LBRX) Accumulated Expenses (2024 - 2026)

Lb Pharmaceuticals has reported Accumulated Expenses for 3 years, with the latest figure at $262000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $262000.0; the trailing twelve-month figure through Mar 2026 stood at $262000.0 (changed N/A YoY), and the FY2025 full-year result was $515000.0, down 35.62% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $262000.0, down from $515000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.1 million in Q3 2025, with the low at $262000.0 in Q1 2026.
• Average Accumulated Expenses over 3 years is $675750.0, with a median of $657500.0 recorded in 2024.
• Peak annual rise in Accumulated Expenses reached 35.62% in 2025, while the deepest fall reached 35.62% in 2025.
• Tracing LBRX's Accumulated Expenses over 3 years: stood at $800000.0 in 2024, then plunged by 35.62% to $515000.0 in 2025, then sank by 49.13% to $262000.0 in 2026.
• The last three Accumulated Expenses figures came in at $262000.0 (Q1 2026), $515000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.

Peer Comparison